Corporate story

Founded in 2015 as a spin-out from Vironova AB, Vironova Medical AB is developing antiviral compounds against herpes and influenza virus. In our portfolio we have patented antiviral molecules with a novel mode of action. In addition, we also have a chemical process technology for thionation of compounds used in pharmaceuticals. Thionating drug molecules can alter characteristics such as bioavailability and result in more potent and selective compounds.

Corporate governance

Board of directors Vironova Medical AB

Mohammed Homman

Mohammed Homman

Mr. Homman has a M.Sc. in Chemistry and B.Sc in biology from Uppsala University in 1998. Mohammed has been the driving force behind the development of the virus analysis technique and VN-180. Mohammed has received several national and international awards in recognition of his entrepreneurship and innovative research achievements. In 2003 Mohammed was chosen as one of the “Leaders of Tomorrow” by the Academy of Achievement, USA.

Alf Sollevi

Alf Sollevi

Professor in anesthesiology and intensive care since 1999 at the Department of Clinical Science, Intervention and Technology at the Karolinska Institute. Dr. Sollevi received his medical degree in 1976 and became a licensed physician in 1978. He received his PhD in 1981. After two years as Associate Professor of Pharmacology, he became a docent in anesthesiology and intensive care in 1986. During a long period, from 1982 to 2008, has Dr. Sollevi lead a research group that conducted basic studies as well as clinical examinations regarding effects and clinical applicability of the endogenous substance adenosine.

Maria Homman

Maria Homman

Maria Homman holds a PhD in polymer technology and has been a manager within R&D at AkzoNobel (initially Casco Adhesives) for 10 years, with responsibility for the development of products from idea to market, as well as customer support. Dr. Maria Homman is currently the COO of Vironova.

Ulf Säther

Ulf Säther

M.Sc. from Stockholm School of Economics. Ulf has 25 years of experience in the pharmaceutical industry, mostly in international and global roles. Most recently 10 years as President Europe in AstraZeneca, based in Brussels, followed by the role as Global Marketing Director at the company headquarters in London. Earlier in his career he also held sales and marketing roles in the US. Board member in RISE (Research Institutes of Sweden), a government body with 2500 employees doing front line research in collaboration with industry, N-side, Leuwen Belgium, a consulting firm in mathematical analysis, Nobelux, a trade org to support trade between Sweden and Belux. Former member of the board at AB Blåklader (working wear) and Chairman in the AZ Germany Supervisory Board. Industrial Advisor at EQT.

Peter Thurell

Peter Thurell

Chairman and CEO of international pharmaceutical company Item Development since 1989, following a period of positions as controller / trouble shooter and/or president in several medium size subsidiaries of Swedish investment group Navigator.Trained in the Royal Swedish Navy (captain), at the University of Lund (law), the University of Stockholm (tax law), the Stockholm School of Economics (BSc in economics and business administration) and IMD in Lausanne (international executive program).

Prof. Jan Bergman

Prof. Jan Bergman

Jan Bergman received his PhD in 1971 from the Royal Institute of Technology in Stockholm, Sweden. He wrote his thesis about the studies of indole derivatives, aromatic heterocyclic organic compounds that are widely distributed components in nature. He continued to focus his research on the studies of complex organic molecules and their application in drug design as biologically active compounds. He was appointed professor in 1990 at Södertörn University College and Karolinska Institute where he supervised over 30 PhD- and 20 post-doctoral students publishing more than 300 scientific articles in the organic chemistry field. He has also contributed as an author/co-author to several organic chemistry books. He has additional academic experience as a chair/editorial board member of numerous international organic chemistry associations. He has been appointed to contribute in peer reviews, professorship evaluations and as a chemistry expert advisor in the court of appeals. He is the inventor of over 10 patent applications for molecules against bacteria, herpes virus, influenza virus, Multiple Sclerosis, Rheumatoid Arthritis and a chemical process called thionation. Since 2005, Emeritus Professor Jan Bergman, has played a significant role in Vironova’s goal to provide drugs that are effective against infectious diseases such as herpes, influenza as well as a european patent-approved chemical process for the thionation of compounds used in pharmaceuticals.

Legal structure

The Vironova Medical Group consists of four companies:

Vironova Medical AB is the mother company.
Vironova Thionation AB, the vehicle for the Thionation project, is a partly owned subsidiary to Vironova Medical as well as Vironova Influenza AB and Vironova Herpes AB.

Intellectual property

Vironova Medical´s patent strategy

Vironova Medical strives to protect all technology and products developed. Patent applications are submitted in all relevant markets for both our chemical process technology and our drug development candidates. Currently Vironova Medical has five different patent families including both active patents and patent applications.

Thionation

Vironova Thionation AB has submitted a patent for a new chemical synthetic method – thionation. The thionation process patent is so far approved in EPC and the thionation reagent patent is granted in U.S. Several patent applications are still pending in the national stage. By applying the thionation method on antiviral substances against influenza, new drug candidates have been synthesized with patents submitted and approved. These patents belong to Vironova Influenza AB.

Herpes

The pharmaceutical candidates against herpes are protected by a patent family that includes all eight human herpes viruses. The patent for the pharmaceutical formulation for topical administration against herpes virus comprising of the B-220 compound has so far been granted in Australia, while other patent applications worldwide are pending. In U.S. granted claims protecting the method of treating a herpes virus infection with a B-220 pharmaceutical formulation has been approved. All anti-herpes patents belong to Vironova Herpes AB.